We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Noninvasive Test Detects Bladder Cancer

By LabMedica International staff writers
Posted on 07 Nov 2017
Image: The ADXBLADDER MCM5 ELISA kit for the diagnosis of bladder cancer (Photo courtesy of Arquer Diagnostics).
Image: The ADXBLADDER MCM5 ELISA kit for the diagnosis of bladder cancer (Photo courtesy of Arquer Diagnostics).
In Europe, bladder cancer represents the fourth most common cancer in men and the 15th most common cancer in women, with 151,000 people diagnosed with the condition in 2012. In order to make a bladder cancer diagnosis, experts currently recommend cystoscopy for all patients with hematuria, in conjunction with computed tomography (CT) urography (in selected high-risk patients) or renal and bladder ultrasound.

At the moment, cystoscopy cannot be replaced by cytology or any other noninvasive tests. Most bladder cancer diagnostic approaches have disadvantages; cystoscopy is an undignified, invasive, and uncomfortable procedure exposing patients to the risk of developing urinary tract infections (UTIs), which are known to occur in around 5% undergoing cystoscopy. Cytology is known to have a low sensitivity and its interpretation is dependent on the user, while CT urogram exposes patients to ionizing radiation.

Urologists at the Northern Institute for Cancer Research (Newcastle Upon Tyne, UK) carried out a prospective blinded study involving 577 hematuria patients in clinics at six centers across the UK between August 2016 and February 2017,who underwent the novel non-invasive testing, with results then compared with the current diagnostic benchmark of combined cystoscopy, ultrasound, and CT scanning.

The team used the ADXBLADDER test that employs standard Enzyme Linked Immunosorbent assay (ELISA) methodology to measure levels of Minichromosome Maintenance Complex Component 5, (MCM5), which is a protein marker of replicating cells, or cells that have the capability to replicate. The test requires just 10 mL of urine and delivers definitive "yes/no" results within three hours.

The ADXBLADDER test received its CE Mark on October 11, 2017. The results of the study showed that 7.96% of the tests were positive for cancer and 92.1% negative. When ADXBLADDER was compared to the gold standard the investigators found that the test correctly identified 95% of patients with high-risk cancers, and that the negative predictive value (the test’s ability to correctly identify patients without cancer) was 97%.

Stuart McCracken, MD, a Consultant Urological Surgeon and the principal investigator, said, “The ADXBLADDER test offers a real game changer in bladder cancer diagnosis. The results of our new study, demonstrating fantastic accuracy, open the way for non- invasive bladder cancer testing to become widespread. This test undoubtedly has a role to play in helping identify women with bladder cancer early which could have a positive impact on survival.” The study was presented at the 37th Société Internationale D'Urologie (SIU) meeting, held October 19-22, 2017, in Lisbon, Portugal.

Related Links:
Northern Institute for Cancer Research

Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Automated MALDI-TOF MS System
EXS 3000

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more